AI assistant
Dr. Lal Pathlabs Limited — Earnings Release 2023
Feb 2, 2023
61783_rns_2023-02-02_77d4e57a-dc53-4d1d-83f8-ac7d54112887.pdf
Earnings Release
Open in viewerOpens in your device viewer
==> picture [587 x 65] intentionally omitted <==
February 02, 2023
National Stock Exchange of India Limited BSE Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (E) Dalal Street Mumbai – 400 051 Mumbai – 400 001
Subject: Press Release for Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Nine Months ended December 31, 2022
Dear Sir/ Madam,
Please find enclosed herewith the Press Release for the Un-audited Financial Results (Standalone and Consolidated) for the Quarter and Nine Months ended December 31, 2022.
Thanking You,
Yours Faithfully,
For Dr. Lal PathLabs Limited
RAJAT KALRA Digitally signed by RAJAT KALRA DN: c=IN, st=Delhi, 2.5.4.20=2d145c0ecf2f9cf63205c8c7bce9364b8240cde06456423498a3b8e9b2e4b0d5, postalCode=110077, street=FLAT NO.2201, 2ND FLOOR, VASHUDHARA CGHS LTD, PLOT NO.1B, SECTOR-22, DWARKA, pseudonym=944ab34be8c224f543bbabe74924faaa, serialNumber=265b090cbfd6acb0b205caeb3a56deb3e7a43b4c8613b597e5cf59dfa51fe365, o=Personal, cn=RAJAT KALRA Date: 2023.02.02 14:21:57 +05'30'
Rajat Kalra Company Secretary and Legal Head
Encl.: As above
==> picture [588 x 67] intentionally omitted <==
February 2, 2023
For Immediate Release
==> picture [159 x 37] intentionally omitted <==
Dr. Lal PathLabs Limited records revenue of Rs 489 Cr in Q3 FY 2022-23
New Delhi, India, February 2, 2023 – Dr. Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended December 31, 2022.
Consolidated Performance Highlights: Q3 FY 2022-23 vs Q3 FY 2021-22
-
Non-Covid Revenue increased by 9.1% in Q3 FY23 to Rs. 478 Cr vs Rs 438 Cr in Q3 FY22
-
Total Revenue declined by 1.5% in Q3 FY23 to Rs. 489 Cr vs Rs 497 Cr in Q3 FY22
-
Covid and Allied contributed 2% to Revenue in Q3 FY23, 12% in Q3 FY22
-
Normalised EBITDA (after adjustment for stock based compensation, CSR) for Q3 FY23 is at Rs. 122 Cr (margins 24.9%) Vs Rs 119 Cr in the same quarter last year
-
Normalised PBT* at Rs 89 Cr, margins 18.2% vs Rs 90 Cr. in Q3 last year
-
Normalised PAT* at Rs 66 Cr, margins 13.5% vs Rs 66 Cr. in Q3 last year
Financial Overview (Consolidated) in Rs Cr
==> picture [391 x 281] intentionally omitted <==
----- Start of picture text -----
Q3 YTD Dec
Particulars
FY23 FY22 Gr % FY23 FY22 Gr %
Revenue 489 497 -1.5% 1526 1602 -4.7%
Non Covid 478 438 9.1% 1474 1272 15.9%
Covid & Allied 11 59 -80.4% 52 330 -84.2%
Expenditure 376 388 -2.9% 1152 1162 -0.9%
EBITDA 113 109 3.4% 374 440 -14.9%
EBITDA Margins 23.1% 22.0% 24.5% 27.4%
RSU & CSR cost 9 9 23 30
Normalised EBITDA 122 119 2.8% 397 470 -15.4%
EBITDA Margins 24.9% 23.9% 26.0% 29.3%
Net other Income/(Interest) 1 3 -1 22
Depreciation Cost 25 23 75 62
Notional Depreciation-SDIPL 12 8 37 8
PBT 76 82 -6.2% 261 391 -33.4%
Margins 15.6% 16.4% 17.1% 24.4%
PAT 54 58 -7.9% 184 288 -36.1%
Margins 11.0% 11.7% 12.1% 18.0%
EPS 6.4 6.9 -7.9% 22.0 34.3 -35.8%
Normalised PBT 89 90 -0.8% 298 399 -25.5%
Margins 18.2% 18.0% 19.5% 24.9%
Normalised PAT 66 66 -0.3% 221 296 -25.3%
Margins 13.5% 13.3% 14.5% 18.5%
----- End of picture text -----
- *Normalised PBT and PAT are excluding notional depreciation.
Cl ~~assification:~~ ~~Internal~~
Dr. Lal Pathlabs Limited
1
12[th] Floor, Tower-B, SAS Tower, Sector-38, Medicity, Gurgaon 122001, Phone: +91 124 3016500, website: www.lalpathlabs.com
==> picture [159 x 37] intentionally omitted <==
About Dr. Lal PathLabs Limited
Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its’ integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.
As on March 31, 2022 the company has 277 clinical laboratories (including National Reference Lab at Delhi, Regional Reference Lab at Kolkata & Bangalore), 4,731 Patient Service Centers (PSCs) and 10,599 Pick-up Points (PUPs). Its’ customers include individual patients, hospitals and other healthcare providers and corporate customers.
Contact Details
Ved Goel Group Chief Financial Officer Dr. Lal PathLabs Limited
+91 124 3016500 [email protected]
Rakshit Tewari/Gargi Mukherjee Adfactors PR
+91 9935551036/+91 9650944756 [email protected] [email protected]
For further information on Dr. Lal PathLabs see www.lalpathlabs.com
Safe Harbour
This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr. Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr. Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.
Classification: Internal
Dr. Lal Pathlabs Limited
12[th] Floor, Tower-B, SAS Tower, Sector-38, Medicity, Gurgaon 122001, Phone: +91 124 3016500, website: www.lalpathlabs.com
2